San Antonio Breast Cancer Symposium 2025
The 2025 San Antonio Breast Cancer Symposium (SABCS) meeting was held December 9-12, 2025 in San Antonio, TX and virtually. Click the links below to read about MBC research reported at this meeting.
Overview of SABCS 2025
- Living Beyond Breast Cancer (video): Dr. Harold J. Burstein reviews important studies reported at SABCS 2025 (studies of HER2+ MBC from 17:02-26:39; studies of HR+, HER- MBC from 37:49-40:00 and 40:57-41:40; studies of triple negative MBC from 40:00-40:57)
- Living Beyond Breast Cancer: This article reviews data presented at SABCS 2025 about drug treatments for the different subtypes of MBC
Brain and Leptomeningeal Metastases
- Reveal Genomics: A new genomic test predicts overall survival and the risk of brain metastases in people with advanced HER2-positive breast cancer
- Breastcancer.org: A small study suggests that datopotamab deruxtecan (Dato-DXd; Datroway®) may help people with breast cancer that has spread to the leptomeninges live longer without their cancer growing if they had not previously received an antibody-drug conjugate (scroll to “Dato-DXd may help treat leptomeningeal disease”)
HER2+ MBC
- Breastcancer.org: Results from the HER2CLIMB-05 clinical trial show that adding tucatinib (Tukysa®) to standard treatments (trastuzumab (Herceptin®) and pertuzumab (Perjeta®)) increases progression-free survival by about 9 months (scroll to “Adding Tukysa…)
ER+, HER2- MBC
Triple Negative MBC
- MedPage Today: More than two-thirds of people with triple negative MBC responded to the bispecific antibody pumitamig plus chemotherapy
Support for Black Women
- Fierce Pharma: TOUCH, the Black Breast Cancer Alliance and Unite for HER reported that their program for Black women with breast cancer called Care for HER helped reduce distress, side effects, and financial concerns
- LinkedIn: You can view the poster here (A LinkedIn account may be required to view this link)